Sponsored Links

Just Announced: (QNTM) Makes an Approx. 42% Move on Breaking News



Any content you receive is for information purposes only. Always conduct your own research.

*Disseminated on Behalf of Quantum BioPharma Ltd.

Krypton Street Is Putting All Eyes On (QNTM) This Morning

—Wednesday, April 1, 2026

Don't Miss The Next Breakout—Get Real-Time Alerts Sent Directly

To Your Phone. Up To 10X Faster Than Email.

Full Coverage On (QNTM) is Starting Right Now

Take A Look At (QNTM) While It's Still Early…

April 1, 2026

Just Announced | (QNTM) Makes an Approx. 42% Move on Breaking News

Dear Reader,

Here at Krypton Street, we're always watching for developments that can shift attention quickly—and a major update just crossed the wire that's putting (QNTM) right in the spotlight.

Quantum BioPharma Ltd. (NASDAQ: QNTM) has our full attention right now following confirmation that the company has formally submitted an Investigational New Dr-ug (IND) application to the U.S. FDA for its lead Multiple Sclerosis candidate, Lucid-MS.

This submission marks a key step forward, supporting the company's planned Phase 2 clinical trial and advancing its broader clinical development timeline.

With Phase 1 already completed and showing a favorable safety profile, the next phase is now positioned to move ahead pending FDA clearance.

At the same time, (QNTM) is already showing strong momentum in the market—tapping $5.44 earlier today, representing an approximate 42% move from yesterday's $3.81 range—while also triggering multiple bullish signals on TradingView's technical analysis platform.

When clinical milestones and technical momentum begin aligning like this, it tends to draw increased attention quickly.

If you missed my earlier email coverage, keep reading to quickly get up to speed on why we're so excited to be highlighting (QNTM) today.

=====

Here at Krypton Street, we're always tracking where breakthrough science meets emerging market momentum—and right now, the biopharmaceutical landscape is showing a clear shift toward data-driven therapeutic development, as advanced computing becomes increasingly important in the search for new treatments.

Companies operating at the intersection of medical research and computational analysis are drawing added attention for their ability to streamline discovery and validation efforts.

This model is becoming especially relevant in areas such as neurodegenerative and metabolic disorders, where unmet medical needs remain significant.

The combination of specialized science and technology-driven analysis is helping shape a new generation of biotech companies with broader strategic flexibility.

Quantum BioPharma Ltd. (NASDAQ: QNTM) is one example of this evolving approach, integrating advanced computing with specialized medical research to support the development of novel candidates.

Which is exactly why (QNTM) just hit our radar and is topping our watchlist this morning—Wednesday, April 1, 2026.

But keep in mind, (QNTM) has less than 4M shares listed as available to the public. When companies have small floats like this, the potential exists for big moves if demand begins to shift.

Analyst Targets Suggest 700% to Over 1,000% Upside Potential

In addition, several analysts have published targets on (QNTM) that imply substantial upside potential from its recent $4 range.

Singular Research set a $35.50 target on (QNTM), which suggests over 700% upside potential.

Kingswood Capital Partners set a $45 target on (QNTM), which suggests over 1,000% upside potential from its recent range.

Inline Image

Formerly known as Lucid BioPharma, the company rebranded to reflect this focus.

With a pipeline spanning neurodegenerative diseases and metabolic disorders, the company is building a hybrid model that connects traditional dr-ug discovery with the next phase of biotech innovation.

And when you begin to look more closely at the company's clinical assets, strategic positioning, and technology-driven model, it becomes easier to see why (QNTM) has started drawing added attention.

Here's a closer look at what is driving our interest.

Integrating Technology and Therapeutics

Quantum BioPharma Ltd. (NASDAQ: QNTM) is a clinical-stage biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory, and metabolic disorders.

The company's mission is to develop novel solutions for brain and inflammatory disorders through a proprietary platform that combines traditional pharmacology with advanced computational analysis.

By focusing on indications with significant patient populations and limited existing treatment options, (QNTM) aims to improve quality of life across a broad patient base.

The company's core strategy involves the dual advancement of its clinical assets and its technology-driven discovery engine.

This approach allows (QNTM) to move its own proprietary candidates through the regulatory path while identifying potential out-licensing pathways early in the development cycle.

Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of its lead compound, Lucid-MS.

Clinical Pipeline and Core Research Areas

Inline Image

The (QNTM) research portfolio is currently prioritized toward therapeutic areas where current standards of care are insufficient, specifically neurodegenerative and neuropsychiatric diseases.

Its lead candidate, Lucid-MS (Lucid-21-302), is a patented new chemical entity designed to prevent and reverse myelin degradation, the underlying mechanism of Multiple Sclerosis (MS).

Unlike current dr-ugs that require injection or infusion, Lucid-MS is being developed as an oral formulation.

Beyond MS, the company has completed dosing in oral toxicity studies supporting a future Investigational New Dr-ug (IND) application for other neurodegenerative conditions.

(QNTM) also invented unbuzzd™, a dietary supplement designed to accelerate alcohol metabolism. A recent double-blind, peer-reviewed clinical trial published in the World Journal of Pharmaceutical and Medical Research demonstrated that unbuzzd™ reduced Blood Alcohol Concentration (BAC) more than 40% faster than a placebo within the first 30 minutes.

Strategic Partnerships and Intellectual Property

A major component of Quantum BioPharma's growth is its commitment to building a robust intellectual property (IP) moat. The company has rights to patent families licensed on an exclusive basis, protecting its neuroprotective compounds and computational discovery algorithms. On March 30, 2026, the company signed a binding Letter of Intent (LOI) with Allucent, a global contract research organization, to conduct a Phase 2 clinical trial for Lucid-MS.

(QNTM) also retains significant financial optionality through its spun-out assets.

The company holds a 19.84% ownership stake in Unbuzzd Wellness Inc. and is entitled to royalty payments of 7% of sales until they reach $250M, at which point the royalty remains at 3% in perpetuity.

Furthermore, the company retains a tax loss carry forward of approximately C$130M, which can be used to offset future tax obligations against profits.

Recent Developments

  • [Phase 2 Trial Milestone]: On March 30, 2026, Quantum announced it expects to initiate the Phase 2 trial for Lucid-MS in the second quarter of 2026, following its strategic partnership with Allucent.
  • [Peer-Reviewed Validation]: On March 23, 2026, a groundbreaking clinical trial for unbuzzd™ was published in a peer-reviewed journal, showing definitive acceleration of BAC reduction and symptom improvement.
  • [Audited Financial Results]: On March 27, 2026, the company released its 2025 year-end audited results, confirming a strong balance sheet with no "going concern" status.
  • [Principal Investigator Appointment]: On March 26, 2026, the company appointed a Principal Investigator for its upcoming MS Phase 2 study, further solidifying its clinical execution plan.
  • [Toxicity Study Completion]: The company completed 180-day repeated dose oral toxicity studies for Lucid-MS, reporting no toxicity or significant side effects, supporting its move into human efficacy trials.

Financial Positioning and Market Potential

As of March 27, 2026, (QNTM) reported cash and digital assets totaling $11.3M. Management believes this provides sufficient working capital to sustain basic operations beyond January 2028, representing a runway of nearly two years. The company also reduced its trade payables by approximately 50% over the last year, from $4.1M to $2.0M.

Operating in the $38B Multiple Sclerosis market (projected by 2030) and the $238B mental health market, Quantum is positioned to capture value through its first-in-class neuroprotective therapies.

With a market capitalization of approximately $22M, the company presents a potential value-inflection point as it transitions into Phase 2 clinical data readouts.

7 Factors Putting (QNTM) On The Top Of This Morning's Watchlist —Wednesday, April 1, 2026…

1. Analyst Coverage: Several analyst targets on (QNTM), including $35.50 from Singular Research and $45 from Kingswood Capital Partners, suggest over 700% to more than 1,000% upside potential from its recent $4 range.

2. Low Float: With fewer than 4M shares listed as available to the public, (QNTM)'s small float could witness the potential for big moves if demand begins to shift.

3. Phase 2: A binding LOI with Allucent and an expected Phase 2 start in Q2 2026 give (QNTM) a near-term clinical milestone to watch.

4. Oral MS: Lucid-MS gives (QNTM) a lead candidate aimed at Multiple Sclerosis with an oral formulation rather than injection or infusion.

5. Peer Review: Published peer-reviewed data showing unbuzzd™ reduced BAC more than 40% faster than placebo within the first 30 minutes adds scientific validation to part of the (QNTM) portfolio.

6. Asset Value: A 19.84% stake in Unbuzzd Wellness, royalty rights tied to sales, and an approximately C$130M tax loss carryforward give (QNTM) several additional balance-sheet and asset-based talking points.

7. Capital Runway: As of March 27, 2026, (QNTM) reported $11.3M in ca-sh and digital assets, with management stating this supports basic operations beyond January 2028.

Take A Look At (QNTM) While It's Still Early…

Inline Image

What continues to stand out about (QNTM) is how multiple factors are beginning to align at the same time. A small float of fewer than 4M shares creates the potential for big moves if demand begins to shift, while published analyst targets suggest 700% to more than 1,000% upside potential from recent levels is putting (QNTM) at the top of our watchlist right now.

At the same time, the expected Phase 2 initiation in Q2 2026 marks an important clinical step forward, supported by a lead MS candidate designed as an oral formulation rather than injection or infusion.

Beyond the pipeline, peer-reviewed data validating unbuzzd™ and a reported $11.3M in ca-sh and digital assets, with runway projected beyond January 2028, add additional layers to the overall picture.

When combined with royalty rights, a 19.84% stake in Unbuzzd Wellness, and a C$130M tax loss carryforward, (QNTM) presents a mix of clinical progress and underlying asset value that could start to draw increased attention.

(QNTM) is our primary focus this morning.

Take a look at (QNTM) while it's still early.

Watch for my next update, it could be hitting any moment.

Sincerely,

Alex Ramsay

Co-Founder / Managing Editor

Krypton Street Newsletter

KryptonStreet.com ("KryptonStreet" or "KS" ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KS is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.

Quantum BioPharma Ltd. (QNTM:US) (QNTM:CA) previously changed their company name and symbols from FSD Pharma Inc. (HUGE:US) (QNTM:CA)

Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired for a period beginning on 03/31/2026 and ending on 04/01/2026 to publicly disseminate information about (QNTM:US) (QNTM:CA) via digital communications. Under this agreement, TD Media LLC has paid Media 1717 LLC seven thousand five hundred USD ("Funds"). To date, including under the previously described agreement, Media 1717 LLC has been paid fifty eight thousand USD ("Funds"). These Funds were part of the thirty five thousand USD funds that TD Media LLC received from a third party named Awareness Consulting Network LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.

Neither Media 1717 LLC, TD Media LLC and their member own shares of (QNTM:US) (QNTM:CA).

Please see important disclosure information here: https://kryptonstreet.com/disclosure/qntm-kIb3k/#details

The Great AI Delusion



Your Retirement Is Dying  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌
fbtwigytin
 

Update your email preferences or unsubscribe here

1607 Ponce De Leon Ave
San Juan, Puerto Rico 00909, Puerto Rico

Terms of Service

Bitcoin's Critical $63K Level: Hold Here or Flush to $30-50K



The Make-or-Break Zone That Determines Whether We Correct Now or Suffer Later
 
   
     
🚨 I’ll be live at 11:30 a.m. ET with Jack Carter🚨

 We’ll share the report with today’s top Triple Income Strategy trades, break down the setups, discuss what’s moving markets and more [tap to join us for Market Masters]
 
Bitcoin's Critical $63K Level: Hold Here or Flush to $30-50K Instead of Later

Bitcoin is approaching a level that could determine whether the market holds steady or unravels far faster than most traders expect.

So today we'll discuss why the $63K zone matters and what it signals about the next major swing.

If this area survives, Bitcoin may grind upward into late spring, but if it fails, the market could flush straight into a deep correction that resets the entire structure.

I'm covering the key signals guiding this setup and why Ethereum's behavior might already be hinting at the path ahead.

If you want to stay ahead of the next big move, make sure you read the full breakdown and see what that $63K line is really telling us.

Get the full story, then join us live at 11:30 a.m. ET weekdays for Market Masters!

 
 
Timing Makes All the Difference
I’m also live at 9:15 a.m. ET weekdays for Morning Monster and at 5 p.m. Tuesdays for 30 Minutes of Awesome — bring your ticker and I’ll analyze it in real time!

Visit me @JeffryTurnmireTrading on YouTube.

_____________________________________________________
 
Have You Seen the 99.7% Historical Edge Backing My $50K Income Challenge?
 
 
You won't believe how straightforward it is to grow a small account consistently using just one trade a day.

Leveraging this one-sided statistical pattern helped me double my trading account over the last year…

 
 
Educational graphic showing "Time to Target: The Bell Curve of Trade Duration" with a red bell curve illustrating three standard deviation thresholds: 68% (1 SD), 95% (2 SD), and 99.7% (3 SD), with explanatory text about trade duration probability and a portrait in the top right corner.
 

And now I'm revealing all the details behind it and more…
 
 
Take a Look in Here Now

_____________________________________________________
 
Today’s Daily Chart Setup: Mesa Laboratories (MLAB)  
 
 
A stock chart showing MLAB bouncing off the Market Roadmap line.
This idea came directly from my Daily Chart Setup that automatically signals potential plays. 

See the strategy behind these signals!
 
MLAB is a new potential entry. Target: 102.05 Stop below: 70.06
MLAB has a historical win rate of 90.91%
MLAB has a profit factor of 9.23
MLAB trades last 102 trading days on average over 22 trades since 1984.

This is for informational and educational purposes only. There is inherent risk in trading, so trade at your own risk. Always remember that past performance is not indicative of future results.

How the Daily Chart Setup Works

Here’s a more detailed description of how the pattern triggers:

 
1. The price breaks upward through the orange Market Roadmap line. 

 
2. Then the price goes up and down while staying above the line. Eventually, it comes down to touch the line again — this could take days, weeks or even months. 

 
3. Once it touches the line and starts moving back up, that signals an entry. 

I use Fibonacci levels for for profit targets and stop losses, and these two tools combined have helped me achieve a 77% win rate over the past six-plus years!
Jeffry Turnmire
Jeffry Turnmire Trading

I host my Morning Monster livestream at 9:15 a.m. ET weekdays on YouTube, and then 30 Minutes of Awesome at 5 p.m. ET each Tuesday!

Visit me @JeffryTurnmireTrading on YouTube.

You can also follow along and join the conversation for real-time analysis, trade ideas, market insights and more in my official Telegram channel!

Important Note: No one from the ProsperityPub team or Jeffry Turnmire Trading will ever message you directly on Telegram. 

I’m just a regular dude in Knoxville, Tennessee: a husband, father, civil engineer, urban farmer, maker and trader.

I've been at this trading thing with real money for 20-plus years, and started paper trading over 35 years ago. I have a knack for making some epic predictions that just may very well come true. Why share them? Because I like helping other people — it's the Eagle Scout in me.



*This is for informational and educational purposes only. There is inherent risk in trading, so trade at your own risk. 
   
 

Share With Friends

Bookmark and Share
 
recipes for healthy food © 2008 | Créditos: Templates Novo Blogger